Non-viral targeted integration at the CISH locus enables CAR-NK cell engineering with enhanced anti-tumor activity
, extended persistence, and reduced exhaustion. Together, these findings highlight CLICK as a highly efficient and versatile platform for non-viral CAR-NK cell engineering, offering a scalable approach for next-generation allogeneic immune cell therapies.
Authors
- Richard Shan
- Jakob Starzyk
- Guozhu Xie (ORCID: https://orcid.org/0000-0002-3377-3099)
- Fei Wang (ORCID: https://orcid.org/0000-0002-2143-9421)
- Keqiang Xie
- Xin Dong
- Jiao Wang
- Hao Wu (ORCID: https://orcid.org/0009-0002-3249-2428)
- Xuemei He
- Yao Sun
Institutions
- Fulcrum Therapeutics (United States) (US)
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Molecular Therapy Oncology
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1016/j.omton.2026.201206
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Science and Technology Planning Project of Guangdong Province